Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2581-2591

  Boixeda, Ramon ^a   Almagro, Pere ^b,c   Díez Manglano, Jesús ^d   Cabrera, Francisco Javier ^e   Recio, Jesús ^f   Martin Garrido, Isabel ^g   Soriano, Joan B ^h  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL ROYO VILLANOVA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL QUIRÓN   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; BACTERIAL FLORA; BACTERIUM CULTURE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COR PULMONALE; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; SPIROMETRY; SPUTUM; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; CLINICAL TRIAL; DISEASE COURSE; HOSPITAL ADMISSION; INTERNAL MEDICINE; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTIONS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERNAL MEDICINE; LUNG; MALE; MIDDLE AGED; PATIENT ADMISSION; PNEUMOCOCCAL INFECTIONS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPAIN; SPUTUM; STREPTOCOCCUS PNEUMONIAE;

EID: 84949508886     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S88702     Document Type: Article

References (39)

1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-1422.
2. Anzueto A. Impact of exacerbation on COPD. Eur Respir Rev. 2010;19:113-118.
3. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-931.
4. De Serres G, Lampron N, La Forge J, et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009;46:129-133.
5. Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891-897.
6. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759-764.
7. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
8. Miravitlles M, Moragas A, Hernández S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013;144(5):1571-1577.
9. Soler N, Esperatti M, Ewig S, Huerta A, Agustí C, Torres A. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J. 2012;40:1344-1353.
10. Miravitlles M, Espinosa C, Fernández-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-46.
11. Monsó E, Rosell A, Bonet G, et al. Lower airway colonization in chronic bronchitis: risk factors. Eur Respir J. 1997;10(Suppl 25):147S.
12. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
13. Miravitlles M, Monsó E, Mensa J, et al. Tratamiento antimicrobiano de la agudización de la EPOC. Arch Bronconeumol. 2008;44:100-108.
14. Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest. 2012;142:1126-1133.
15. Guía Española del EPOC (Gesepoc). Arch Bronconeumol. 2012;48(Suppl 1):2-58.
16. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http://www.goldcopd.org/. Accessed January 2, 2015.
17. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
18. Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-586.
19. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL; a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
20. Soler-Cataluña JJ, Martínez-García MA, Sanchez LS, Tordera MP, Sánchez PR. Sever exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2008;103(5):682-689.
21. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339-344.
22. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-1548.
23. Larsen MV, Janner JH, Nielsen SD, Friis-Moller A, Ringbaek T, Lange P. Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital. Scand J Infect Dis. 2009;41:26-32.
24. Roche N, Kouassi B, Rabbat A, Mounedji A, Lorut C, Huchon G. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration. 2007;74:19-25.
25. Almagro P, Salvadó M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration. 2012;84:36-43.
26. Nowetaka K, Frankowska M, Grzelewska-Rzymowska I. Exacerbations of COPD and the role of sputum bacteriological examination. Pneumonol Alergol Pol. 2006;74:396-402.
27. García-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072-1078.
28. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238-243.
29. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662-671.
30. Bari MR, Hiron MM, Zaman SM, Rahman MM, Ganguly KC. Microbes responsible for acute exacerbation of COPD. Mymensingh Med J. 2010;19:576-585.
31. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis. 2011;52(S4):S290-S295.
32. Balter M. Canadian guidelines. Can Respir J. 2003;10:248-258.
33. Woodhead M. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;1138-1180.
34. Daniels JM, de Graaf CS, Vlaspolder F, Snijders D, Jansen HM, Boersma WG. Sputum color reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of COPD. Clin Microbiol Infect. 2010;16:583-588.
35. Tsimogianni AM, Papiris SA, Kanavaki S, et al. Predictors of positive sputum cultures in exacerbation of COPD. Respirology. 2009;14:1114-1120.
36. Bafadhel M, Haldar K, Barker B, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J COPD. 2015;10:1075-1083.
37. Stolz D, Tamm M. Discriminate use of antibiotics for exacerbation of COPD. Curr Opin Pulm Med. 2009;15:126-132.
38. San Román Terán C, Guijarro Merino R, Gómez Huelgas R, Montero Ribas L. Epidemiología hospitalaria de la EPOC en España. Rev Clin Esp. 2007;207(Suppl 1):3-7.
39. Pozo-Rodríguez F, Alvarez CJ, Castro-Acosta A, et al; AUDIPOC Spain Group. Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): method and organisation. Arch Bronconeumol. 2010;46:349-357.